secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2023-06-13T23:59:59+00:00
Accession:  0000950170-23-027644
Event type: other
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx annual meeting approves 2023 Incentive Plan and A&R ESPP; three directors re-elected
--------------------------------------------------------------------------------

- Stockholders elected Class I directors Emil Kakkis (58.8M for), Shehnaaz Suliman (55.7M for), Daniel Welch (52.3M for).
- 2023 Incentive Plan approved: 42.0M for, 18.0M against; 5.0M broker non-votes.
- A&R ESPP approved with 59.7M for, 262,515 against.
- Ernst & Young ratified as independent auditor for FY2023 (63.99M for, 934,903 against).
- Advisory say-on-pay passed with 56.7M for, 3.2M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000095017023027644/0000950170-23-027644-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000095017023027644/rare-20230607.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-027644

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer